Pharma News

The U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis (scarring), liver cancer, liver failure, and even death.

Gilead Sciences and the World Health Organization have expanded their long-standing partnership to accelerate the elimination of visceral leishmaniasis (VL), also known as kala-azar, one of the world’s deadliest parasitic diseases.

Venus Remedies has achieved a major milestone after receiving Marketing Authorization from the Saudi Food and Drug Authority for its specialty oncology therapy Plerixafor. The approval marks the company’s first-ever global authorization for the drug and strengthens its growing focus on complex injectable therapies in regulated international markets.

Dr. Reddy’s Laboratories has announced the launch of Obeda® tablets, an oral semaglutide therapy for patients with diabetes in India. The launch marks another major step in the company’s expansion of its GLP-1 portfolio after recently introducing semaglutide injections in India and Canada.

Eli Lilly has announced encouraging results from its late-stage Phase 3 clinical trial of retatrutide, an investigational next-generation obesity treatment that delivered dramatic weight reduction in adults living with obesity or overweight conditions.

The Central Drugs Standard Control Organisation (CDSCO) has issued a public notice clarifying that cosmetic products cannot be used through injections and are not permitted for treatment purposes under Indian law.

The notice, released by the Directorate General of Health Services under the Ministry of Health and Family Welfare, comes amid rising use of aesthetic and beauty procedures in clinics and salons across the country.

A promising targeted therapy may offer new hope to children and adults living with fibrous dysplasia, a rare bone disorder that weakens bones and severely affects mobility. Researchers have reported that the drug burosumab significantly improved phosphate balance and physical function in patients suffering from the debilitating condition.

India has once again delivered a setback to global pharmaceutical major AbbVie after the company lost its attempt to secure patent protection for its Hepatitis C therapy in the country, a move that could strengthen access to affordable generic medicines.